Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Recombinant, human VEGFR-2 consisting of all 7 immunoglobulin-like extracellular domains, but lacking the single transmembrane region and the intracellular split tyrosine kinase domain expressed in S. frugiperda insect cells. Binding of ligand to the full-length VEGFR-2 results in a high signaling activity and mitogenic activity in endothelial cells.
VEGFR2D1-7, Human, Recombinant, S. frugiperda 分析证书
标题
批号
676490
参考
参考信息概述
Robinson, C.J., and Stringer, S.E. 2001 J. Cell Sci.114, 853. Roeckl, W., et al. 1998. Exp. Cell Res.241, 161.
数据表
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
Recombinant, human VEGFR-2 consisting of all 7 immunoglobulin-like extracellular domains, but lacking the single transmembrane region and the intracellular split tyrosine kinase domain expressed in S. frugiperda insect cells. Contains all of the domains necessary for high affinity binding to VEGF. VEGFR-2 has a lower affinity for VEGF165 than VEGFR-1. However, VEGFR-2 has a higher signaling activity and is reported to mediate almost all observed endothelial cell responses to VEGF, including the increased microvascular permeability and endothelial cell proliferation. VEGFR-2 requires heparin for binding VEGF165.
Form
Lyophilized
Formulation
Lyophilized from 100 mM NaCl, 25 mM MES, pH 5.5.
Purity
≥90% by SDS-PAGE
Biological activity
Measured by the ability to inhibit VEGF165-induced proliferation in human umbilical vein endothelial (HUVE) cells
Solubility
Aqueous buffers (≥100 µg/ml) or H₂O (≥100 µg/ml)
Storage
≤ -70°C
Do Not Freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 6 months at -70°C. Avoid freeze/thaw cycles of solutions.
Toxicity
Standard Handling
References
Robinson, C.J., and Stringer, S.E. 2001 J. Cell Sci.114, 853. Roeckl, W., et al. 1998. Exp. Cell Res.241, 161.